ArticleInternational urology and nephrology2024

Docetaxel versus androgen receptor signaling inhibitor (ARSI) against chemo-naïve castration-resistant prostate cancer (CRPC): propensity score matched analysis in real world.

Tatsuya Shimomura et al.PubMed ↗Publisher ↗

No numbers read from the abstract.